Cost Minimization Analysis of Insulin Glargine 300 U/Ml Vs Glargine 100 U/Ml for the Management of Type 2 Diabetes from A Private and Public Third-Party Payer Perspective in Chile
May 1, 2018, 00:00
10.1016/j.jval.2018.04.506
https://www.valueinhealthjournal.com/article/S1098-3015(18)30806-4/fulltext
Title :
Cost Minimization Analysis of Insulin Glargine 300 U/Ml Vs Glargine 100 U/Ml for the Management of Type 2 Diabetes from A Private and Public Third-Party Payer Perspective in Chile
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30806-4&doi=10.1016/j.jval.2018.04.506
First page :
Section Title :
Open access? :
No
Section Order :
1312